Efficacy of mefloquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum infection in Machinga District, Malawi, 1998.

J MacArthur Malaria Epidemiology Branch, Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30341-3717, USA. jmacarthur@cdc.gov

Search for other papers by J MacArthur in
Current site
Google Scholar
PubMed
Close
,
G M Stennies Malaria Epidemiology Branch, Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30341-3717, USA. jmacarthur@cdc.gov

Search for other papers by G M Stennies in
Current site
Google Scholar
PubMed
Close
,
A Macheso Malaria Epidemiology Branch, Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30341-3717, USA. jmacarthur@cdc.gov

Search for other papers by A Macheso in
Current site
Google Scholar
PubMed
Close
,
M S Kolczak Malaria Epidemiology Branch, Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30341-3717, USA. jmacarthur@cdc.gov

Search for other papers by M S Kolczak in
Current site
Google Scholar
PubMed
Close
,
M D Green Malaria Epidemiology Branch, Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30341-3717, USA. jmacarthur@cdc.gov

Search for other papers by M D Green in
Current site
Google Scholar
PubMed
Close
,
D Ali Malaria Epidemiology Branch, Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30341-3717, USA. jmacarthur@cdc.gov

Search for other papers by D Ali in
Current site
Google Scholar
PubMed
Close
,
L M Barat Malaria Epidemiology Branch, Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30341-3717, USA. jmacarthur@cdc.gov

Search for other papers by L M Barat in
Current site
Google Scholar
PubMed
Close
,
P N Kazembe Malaria Epidemiology Branch, Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30341-3717, USA. jmacarthur@cdc.gov

Search for other papers by P N Kazembe in
Current site
Google Scholar
PubMed
Close
, and
T K Ruebush 2nd Malaria Epidemiology Branch, Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30341-3717, USA. jmacarthur@cdc.gov

Search for other papers by T K Ruebush 2nd in
Current site
Google Scholar
PubMed
Close
Restricted access

In response to the spread of chloroquine-resistant Plasmodium falciparum, Malaŵi changed its first-line antimalarial drug in 1993 from chloroquine to sulfadoxine-pyrimethamine (SP). Surveillance data has suggested that resistance to SP may be increasing. We compared the efficacy of SP with a potential successor, mefloquine (MQ). By use of a modified World Health Organization in vivo protocol, children infected with P. falciparum were randomized to receive SP (sulfadoxine 25 mg/kg) or MQ (15 mg/kg). We observed combined RII and RIII parasitologic failures of 20.0 and 22.0% in the SP and MQ arms, respectively. Among those in the MQ arm, the relative hazard of failing with a Day 2 drug level < 500 ng/mL was 10.6 times higher than those with levels > or = 500 ng/mL. Given the decreased efficacy of the first-line antimalarial drug and the high failure rates of MQ at this lower dosage, Malaŵi should consider assessing the efficacy and feasibility of alternative drugs to treat uncomplicated falciparum malaria.

Author Notes

Save